|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
She J, Yang P, Hong Q and Bai C: Lung
cancer in China: Challenges and interventions. Chest.
143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 world health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
5
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Screening for epidermal growth factor receptor mutations in
lung cancer. N Engl J Med. 361:958–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang SF, Liu HP, Li LH, Ku YC, Fu YN,
Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, et al: High frequency
of epidermal growth factor receptor mutations with complex patterns
in non-small cell lung cancers related to gefitinib responsiveness
in Taiwan. Clin Cancer Res. 10:8195–8203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pao W and Miller VA: Epidermal growth
factor receptor mutations, small-molecule kinase inhibitors, and
non-small-cell lung cancer: Current knowledge and future
directions. J Clin Oncol. 23:2556–2568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giaccone G and Rodriguez JA: EGFR
inhibitors: What have we learned from the treatment of lung cancer?
Nat Clin Pract Oncol. 2:554–561. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-
Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol.
15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Inoue A, Kobayashi K, Maemondo M, Suqawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Updated overall survival results from a randomized phase III
trial comparing gefitinib with carboplatin-paclitaxel for
chemo-naïve non-small cell lung cancer with sensitive EGFR gene
mutations (NEJ002). Ann Oncol. 24:54–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H and Hirashima T:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small cell lung cancer harboring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao W, Wang H, Xie J and Tian B: A
clinicopathological study of small lung adenocarcinoma 1 cm or less
in size: Emphasis on histological subtypes associated with lymph
node metastasis and recurrence. Int J Surg Pathol. 26:4–11. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshizawa A, Sumiyoshi S, Sonobe M,
Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H
and Haga H: Validation of the IASLC/ATS/ERS lung adenocarcinoma
classification for prognosis and association with EGFR and KRAS
gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol.
8:52–61. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yanagawa N, Shiono S, Abiko M, Ogata SY,
Sato T and Tamura G: The correlation of the international
association for the study of lung cancer (IASLC)/American thoracic
society (ATS)/European respiratory society (ERS) classification
with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac
Surg. 98:453–458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: WHO classification of tumors of lung, pleural,
thymus and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G,
Garg K, et al: International association for the study of lung
cancer/American thoracic society/European respiratory society:
International multidisciplinary classification of lung
adenocarcinoma: Executive summary. Proc Am Thorac Soc. 8:381–385.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou C, Zhao J, Shao J and Li W:
Prognostic relevance of TTF-1 expression in stage I adenocarcinoma.
Oncotarget. 8:107462–107468. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kadota K, Nitadori J, Sarkaria IS, Sima
CS, Jia X, Yoshizawa A, Rusch VW, Travis WD and Adusumilli PS:
Thyroid transcription factor-1 expression is an independent
predictor of recurrence and correlates with the IASLC/ATS/ERS
histologic classification in patients with stage I lung
adenocarcinoma. Cancer. 119:931–938. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barletta JA, Perner S, Iafrate AJ, Yeap
BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis
WD, et al: Clinical significance of TTF-1 protein expression and
TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med.
13:1977–1986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G,
Garg K, et al: International association for the study of lung
cancer/American thoracic society/European respiratory society
international multidisciplinary classificatiosn of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fridlender ZG, Sun J, Kim S, Kapoor V,
Cheng G, Ling L, Worthen GS and Albelda SM: Polarization of
tumor-associated neutrophil phenotype by TGF-beta: ‘N1’ versus ‘N2’
TAN. Cancer Cell. 16:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cedres S, Torrejon D, Martinez A, Martinez
P, Navarro A, Zamora E, Mulet-Margalef N and Felip E: Neutrophil to
lymphocyte ratio (NLR) as an indicator of poor prognosis in stage
IV non-small cell lung cancer. Clin Transl Oncol. 14:864–869. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
D'Angelo SP, Janjiqian YY, Ahye N, Riely
GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, et al:
Distinct clinical course of EGFR-mutant resected lung cancers:
Results of testing of 1118 surgical specimens and effects of
adjuvant gefitinib and erlotinib. J Thorac Oncol. 7:1815–1822.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshizawa A, Motoi N, Riely GJ, Sima CS,
Gerald WL, Kris MG, Park BJ, Rusch VW and Travis WD: Impact of
proposed IASLC/ATS/ERS classification of lung adenocarcinoma:
Prognostic subgroups and implications for further revision of
staging based on analysis of 514 stage I cases. Mod Pathol.
24:653–664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ning H, Liu M, Wang L, Yang Y, Song N, Xu
X, Ju J and Jiang G: Clinicopathological features of Chinese lung
cancer patients with epidermal growth factor receptor mutation. J
Thorac Dis. 9:796–801. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang
T, Han Y, Huang L, Zhu Y, Li X and Yan X: EGFR mutations in
surgically resected fresh specimens from 697 consecutive Chinese
patients with non-small cell lung cancer and their relationships
with clinical features. Int J Mol Sci. 14:24549–24559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thakur MK and Gadgeel SM: Predictive and
prognostic biomarkers in non-small cell lung cancer. Semin Respir
Crit Care Med. 37:760–770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gazdar AF and Minna JD: Deregulated EGFR
signaling during lung cancer progression: Mutations, amplicons, and
autocrine loops. Cancer Prev Res (Phila). 1:156–160. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shroff GS, de Groot PM,
Papadimitrakopoulou VA, Truong MT and Carter BW: Targeted therapy
and immunotherapy in the treatment of non-small cell lung cancer.
Radiol Clin North Am. 56:485–495. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ciuffreda L, Incani UC, Steelman LS,
Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari
S, Cognetti F, et al: Signaling intermediates (MAPK and PI3K) as
therapeutic targets in NSCLC. Curr Pharm Des. 20:3944–3957. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo J, Solimini NL and Elledge SJ:
Principles of cancer therapy: Oncogene and non-oncogene addiction.
Cell. 136:823–837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cooper WA, O'toole S, Boyer M, Horvath L
and Mahar A: What's new in non-small cell lung cancer for
pathologists: The importance of accurate subtyping, EGFR mutations
and ALK rearrangements. Pathology. 43:103–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gadgeel SM, Ramalingam SS and Kalemkerian
GP: Treatment of lung cancer. Radiol Clin North Am. 50:961–974.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong
Z, Lu S, Cheng Y, Han B, Chen L, et al: First-line erlotinib versus
gemcitabine/cisplatin in patients with advanced EGFR
mutation-positive non-small-cell lung cancer: Analyses from the
phase III, randomized, open-label, ENSURE study. Ann Oncol.
26:1883–1889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lungcancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han JY, Park K, Kim SW, Lee DH, Kim HY,
Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, et al: First-SIGNAL:
First-line single-agent iressa versus gemcitabine and cisplatin
trial in never-smokers with adenocarcinoma of the lung. J Clin
Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Boolell V, Alamgeer M, Watkins DN and
Ganju V: The evolution of therapies in non-small cell lung cancer.
Cancers (Basel). 7:1815–1846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ryska A, Dziadziuszko R, Olszewski W,
Berzinec P, Oz B, Gottfried M, Cufer T, Samarzija M, Plank L,
Ostoros G and Timar J: Molecular diagnostics of lung cancer. Magy
Onkol. 59:259–266. 2015.PubMed/NCBI
|
|
44
|
Janjigian YY, Park BJ, Zakowski MF,
Ladanyi M, Pao W, D'Angelo SP, Kris MG, Shen R, Zheng J and Azzoli
CG: Impact on disease-free survival of adjuvant erlotinib or
gefitinib in patients with resected lung adenocarcinomas that
harbor EGFR mutations. J Thorac Oncol. 6:569–575. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang Q, Wang H, Li P, Zhu H, He C, Wei B,
Ma J and Ma Z: Erlotinib-based perioperative adjuvant therapy for a
case of unresectable stage IIIA (N2) nonsmall cell lung cancer. Am
J Med Sci. 340:321–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lara-Guerra H, Chung CT, Schwock J,
Pintilie M, Hwang DM, Leighl NB, Waddell TK and Tsao MS:
Histopathological and immunohistochemical features associated with
clinical response to neoadjuvant gefitinib therapy in early stage
non-small cell lung cancer. Lung Cancer. 76:235–241. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schaake EE, Kappers I, Codrington HE,
Valdes Olmos RA, Teertstra HJ, van Pel R, Burgers JA, van Tinteren
H and Klomp HM: Tumor response and toxicity of neoadjuvant
erlotinib in patients with early-stage non-small-cell lung cancer.
J Clin Oncol. 30:2731–2738. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tokumo M, Toyooka S, Kiura K, Shigematsu
H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, et al:
The relationship between epidermal growth factor receptor mutations
and clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
49
|
Sonobe M, Manabe T, Wada H and Tanaka F:
Mutations in the epidermal growth factor receptor gene are linked
to smoking-independent, lung adenocarcinoma. Br J Cancer.
93:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Usuda K, Sagawa M, Motono N, Ueno M,
Tanaka M, Machida Y, Matoba M, Taniguchi M, Tonami H, Ueda Y and
Sakuma T: Relationships between EGFR mutation status of lung cancer
and preoperative factors-Are they predictive? Asian Pac J Cancer
Prev. 15:657–662. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chung KP, Huang YT, Chang YL, Yu CJ, Yang
CH, Chang YC, Shih JY and Yang PC: Clinical significance of thyroid
transcription factor-1 in advanced lung adenocarcinoma under
epidermal growth factor receptor tyrosine kinase inhibitor
treatment. Chest. 141:420–428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang Y, Wang R, Li Y, Pan Y, Hu H, Zhang
Y, Li H, Shen L, Yu Y, Sun Y and Chen H: Negative thyroid
transcription factor 1 expression defines an unfavorable subgroup
of lung adenocarcinomas. J Thorac Oncol. 10:1444–1450. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu
X, Jheon S, Lee CT, Lee JS and Chung JH: High incidence of EGFR
mutations in Korean men smokers with no intratumoral heterogeneity
of lung adenocarcinomas: Correlation with histologic subtypes,
EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol.
7:323–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shanzhi W, Yiping H, Ling H, Jianming Z
and Qiang L: The relationship between TTF-1 expression and EGFR
mutations in lung adenocarcinomas. PLoS One. 9:e954792014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yamaguchi T, Yanagisawa K, Sugiyama R,
Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H
and Takahashi T: NKX2-1/ TITF1/ TTF-1-induced ROR1 is required to
sustain EGFR survival signaling in lung adenocarcinoma. Cancer
Cell. 21:348–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Huang TW, Lin KF, Lee CH, Chang H, Lee SC
and Shieh YS: The role of thyroid transcription factor-1 and tumor
differentiation in resected lung adenocarcinoma. Sci Rep.
7:142222017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee HO, Mullins SR, Franco-Barraza J,
Valianou M, Cukierman E and Cheng JD: FAP-overexpressing
fibroblasts produce an extracellular matrix that enhances invasive
velocity and directionality of pancreatic cancer cells. BMC Cancer.
11:2452011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Brambilla E, Le Teuff G, Marguet S,
Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le
Chevalier T, Filipits M, et al: Prognostic effect of tumor
lymphocytic infiltration in resectable non-small-cell lung cancer.
J Clin Oncol. 34:1223–1230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomized, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kadota K, Villena-Vargas J, Yoshizawa A,
Motoi N, Sima CS, Riely GJ, Rusch VW, Adusumilli PS and Travis WD:
Prognostic significance of adenocarcinoma in situ, minimally
invasive adenocarcinoma, and nonmucinous lepidic predominant
invasive adenocarcinoma of the lung in patients with stage I
disease. Am J Surg Pathol. 38:448–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kaseda K, Asakura K, Kazama A and Ozawa Y:
Clinicopathological and prognostic features of surgically resected
pathological stage I lung adenocarcinoma harboring epidermal growth
factor receptor and K-ras mutation. Thorac Cancer. 8:229–237. 2017.
View Article : Google Scholar : PubMed/NCBI
|
